Medios agrees to acquire 74% of Caelo to expand European pharmaceutical ingredients business
- nuaxia
- 4일 전
- 2분 분량
The acquisition would add Caelo’s €40 million-revenue API and excipients business and establish the German company as the anchor of Medios’ planned European network for pharmaceutical compounding ingredients.
Medios has signed an agreement to acquire a 74% majority stake in Caesar & Loretz (Caelo), a German supplier of active pharmaceutical ingredients, excipients and raw materials to pharmacies, hospitals and industrial customers, with financial terms not disclosed.
The transaction would broaden Medios’ pharmacy offering while bringing Caelo together with existing operations in Belgium and Spain to form a European platform for APIs and excipients.
Field | Content |
Alert Type | Deal |
Companies | Medios AG; Caesar & Loretz GmbH (Caelo) |
Deal Type | Acquisition of majority stake |
Asset or Company | 74% majority stake in Caesar & Loretz GmbH (Caelo) |
Technology or Modality | Active pharmaceutical ingredients (APIs), excipients and pharmaceutical raw materials |
Deal Value | Financial terms have not been disclosed. Caelo expects revenue of approximately €40 million in the current financial year, but this represents company revenue rather than transaction consideration. (WebDisclosure) |
Geography | Germany; Europe |
What Happened | On 11 August 2026, Medios signed an agreement to acquire a 74% stake in Caelo, subject to antitrust approval. Caelo employs approximately 240 people at GMP-certified sites in Hilden and Bonn and supplies APIs, excipients and raw materials to pharmacies, hospitals and industrial customers. Following completion, Caelo will continue operating independently under its existing brand and management, with its Hilden and Bonn sites remaining its operational base. (WebDisclosure) |
Why It Matters | The acquisition extends Medios’ offering further into the pharmaceutical supply chain, allowing it to provide pharmacies with finished medicines, sterile compounding services and ingredients for their own formulations. Caelo would also provide a German base for expanding Medios’ existing API and excipients activities across Europe, where common GMP standards allow these ingredients to be traded across borders. (WebDisclosure) |
Supporting Context | Medios already operates in the API and excipients market through Magis Pharma in Belgium and Metapharmaceutical in Spain. Caelo would become the German anchor of these activities, which Medios plans to consolidate under its new Medios Holding Compounding Essentials GmbH structure. (WebDisclosure) |
Strategic Rationale | Medios gains Caelo’s established pharmacy customer relationships, GMP-certified infrastructure and API and excipients portfolio, while Caelo gains access to Medios’ distribution network and international reach. The companies’ offerings are described as complementary rather than overlapping. (WebDisclosure) |
Potential Impact | Medios intends to use the combined platform to broaden its product range and progressively extend its API and excipients activities into additional European markets. The acquisition is not expected to have a material impact on Medios’ 2026 Group forecast. (WebDisclosure) |
Key Takeaway | The Caelo acquisition would give Medios a German anchor for a wider European API and excipients network while expanding the range of pharmaceutical products it can supply to pharmacies. |
What to Watch | Antitrust approval and transaction completion, followed by further details on Medios’ European expansion plans; the company said additional information would be provided with its half-year report on 12 August 2026 and at its Capital Markets Day on 29 September 2026. (WebDisclosure) |
Primary Source | |
Relevant Date | 11 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글